Adherence to antipsychotic medications

Journal of Clinical Psychiatry

Volumn 60, Issue SUPPL. 21, 1999, Pages 25-30

  Perkins, Diana O ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

HUMAN; ILLNESS BEHAVIOR; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW;

EID: 0032746140     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986;14: 105-122
2. Weiden P, Rapkin B, Mott T, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 1994;20:297-310
3. Ayuso-Gutierrez JL, del Rio V. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997;28:199-206
4. Steadman HJ, Mulvey EP, Monahan J, et al. Violence by people discharged from acute psychiatric inpatient facilities and by others in the same neighborhoods. Arch Gen Psychiatry 1998;55:393-401
5. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991;17:325-351
6. Lieberman JA, Sheitman B, Chakos M, et al. The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective. J Clin Psychopharmacol 1998;18(suppl 1):20S-24S
7. Kane JM, Casey DE, Daniel DG, et al. Antipsychotic agents: minimizing side effects to maximize compliance. J Clin Psychiatry Intercom: The Experts Converse Oct 1, 1996:1-12
8. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997;17:194-201
9. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia [see comments]. Am J Psychiatry 1994;151:825-835
10. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40
11. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
12. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-167
13. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233-246
14. Becker MH, Maiman LA. Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care 1975;13:10-24
15. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-651
16. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992;22:787-797
17. Agarwal MR, Sharma VK, Kishore KK, et al. Non-compliance with treatment in patients suffering from schizophrenia: a study to evaluate possible contributing factors. Int J Soc Psychiatry 1998;44:92-106
18. Adams SG Jr, Howe JT. Predicting medication compliance in a psychotic population. J Nerv Ment Dis 1993;181:558-560
19. Van Dongen CJ. Is the treatment worse than the cure? attitudes toward medications among persons with severe mental illness. J Psychosoc Nurs Ment Health Serv 1997;35:21-25
20. Ruscher SM, de Wit R, Mazmanian D. Psychiatric patients' attitudes about medication and factors affecting noncompliance. Psychiatr Serv 1997;48: 82-85
21. Silva RR, Munoz DM, Daniel W, et al. Causes of haloperidol discontinuation in patients with Tourette's disorder: management and alternatives. J Clin Psychiatry 1996;57:129-135
22. Weiss RD, Greenfield SF, Najavits LM. et al. Medication compliance among patients with bipolar disorder and substance use disorder. J Clin Psychiatry 1998;59:172-174
23. Buis W. Patients' opinions concerning side effects of depot neuroleptics [letter]. Am J Psychiatry 1992;149:844-845
24. Gitlin MJ, Cochran SD, Jamison KR. Maintenance lithium treatment: side effects and compliance. J Clin Psychiatry 1989;50:127-131
25. Kemp R, David A. Psychological predictors of insight and compliance in psychotic patients. Br J Psychiatry 1996;169:444-450
26. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10(suppl 3): 133-138
27. Van Putten T, May PR, Marder SR, et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981;38:187-190
28. Weiden PJ, Mann JJ, Dixon L, et al. Is neuroleptic dysphoria a healthy response? Compr Psychiatry 1989;30:546-552
29. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993;19:609-618
30. Seltzer A, Roncari I, Garfinkel P. Effect of patient education on medication compliance. Can J Psychiatry 1980;25:638-645
31. Camey MW, Sheffield BF. Comparison of antipsychotic depot injections in the maintenance treatment of schizophrenia. Br J Psychiatry 1976;129: 476-481
32. Kelly GR, Mamon JA, Scott JE. Utility of the health belief model in examining medication compliance among psychiatric outpatients. Soc Sci Med 1987;25:1205-1211
33. Montgomery SA, Kasper S. Side effects, dropouts from treatment and cost consequences. Int Clin Psychopharmacol 1998;13(suppl 2):S1-S5
34. Falloon I, Watt DC, Shepherd M. A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med 1978;8:59-70
35. Gillis LS, Trollip D, Jakoet A, et al. Non-compliance with psychotropic medication. S Afr Med J 1987;72:602-606
36. Lin IF, Spiga R, Fortsch W. Insight and adherence to medication in chronic schizophrenics. J Clin Psychiatry 1979;40:430-432
37. Sullivan G, Wells KB, Morgenstern H, et al. Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. Am J Psychiatry 1995;152:1749-1756
38. Owen RR, Fischer EP, Booth BM, et al. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996; 47:853-858
39. Pristach CA, Smith CM. Medication compliance and substance abuse among schizophrenic patients. Hosp Community Psychiatry 1990;41: 1345-1348
40. Weiden P, Rapkin B, Zygmunt A, et al. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv 1995;46:1049-1054
41. Marder SR, Mebane A, Chien CP, et al. A comparison of patients who refuse and consent to neuroleptic treatment. Am J Psychiatry 1983;140:470-472
42. McEvoy JP, Howe AC, Hogarty GE. Differences in the nature of relapse and subsequent inpatient course between medication-compliant and noncompliant schizophrenic patients. J Nerv Ment Dis 1984;172:412-416
43. Van Putten T, Crumpton E, Yale C. Drug refusal in schizophrenia and the wish to be crazy. Arch Gen Psychiatry 1976;33:1443-1446
44. Smith CM, Barzman D, Pristach CA. Effect of patient and family insight on compliance of schizophrenic patients. J Clin Pharmacol 1997;37:147-154
45. Crawford R, Forrest A. Controlled trial of depot fluphenazine in out-patient schizophrenics. Br J Psychiatry 1974;124:385-391
46. Davies A, Langley PC, Keks NA, et al. Risperidone versus haloperidol, II: cost-effectiveness. Clin Ther 1998;20:196-213
47. Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry 1997;58(suppl 10): 50-54
48. Bech P, Vendsborg PB, Rafaelsen OJ. Lithium maintenance treatment of manic-melancholic patients: its role in the daily routine. Acta Psychiatr Scand 1976;53:70-81
49. Kelly GR, Scott JE, Mamon J. Medication compliance and health education among outpatients with chronic mental disorders [published erratum appears in Med Care 1991;29:889]. Med Care 1990;28:1181-1197
50. Eckman TA, Wirshing WC, Marder SR, et al. Technique for training schizophrenic patients in illness self-management: a controlled trial. Am J Psychiatry 1992;149:1549-1555
51. Robinson GL, Gilbertson AD, Litwack L. The effects of a psychiatric patient education to medication program on post-discharge compliance. Psychiatr Q 1986;58:113-118
52. Hornung WP, Klingberg S, Feldmann R, et al. Collaboration with drug treatment by schizophrenic patients with and without psychoeducational training: results of a 1-year follow-up. Acta Psychiatr Scand 1998;97: 213-219
53. Davidson L, McGlashan TH. The varied outcomes of schizophrenia. Can J Psychiatry 1997;42:34-43
54. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997;102:43-49